For many patients, this involves combination therapy using: PT-141 injections (Bremetide) to activate sexual desire and central arousal PDE5 inhibitors or compounded therapies like Erexafil to boost blood flow and erectile response Hormone replacement therapy is recommended if low testosterone is identified Sublingual medications for rapid-onset enhancement when needed This protocol also considers comorbidities such as high blood pressure, diabetes, or neurological conditions, ensuring that treatment is safe, effective, and aligned with broader health goals
Otero-Vias M, Falanga V
GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone
It promotes youthful, radiant skin and slows aging
Biomed Pharmacotherapy 175:116709
Eligibility typically requires a BMI of 30 kg/m or higher, or BMI of 27 kg/m or higher with weight-related comorbidities such as hypertension, dyslipidemia, or obstructive sleep apnea
